EU to strengthen ethical assessment of trial data in drug approval dossiers
This article was originally published in Scrip
Executive Summary
Pharmaceutical companies submitting new European drug approval applications involving data from clinical trials conducted outside the EU can expect to have this data more closely scrutinised for conformity to ethical and GCP standards under new guidance that comes into force next month.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.